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Abstract
Mucopolysaccharidosis IVA (MPS IVA; Morquio A), is a lysosomal storage
disorder characterized by the deficiency of N-acetylgalactosamine-6-sulfatase (GALNS),
resulting in the accumulation of glycosaminoglycans (GAGs) such as keratan sulfate
(KS) (Northover et al., 1996) and chondroitin-6-sulfate. There is no applicable animal
model or appropriate cell lines currently available for the study of MPS IVA. Furthermore,
patient-specific material is limited and difficult to obtain, rendering the study of MPSIVA
pathogenesis challenging. Thus, the generation of an induced pluripotent stem cell
(iPSC) line from patient-specific somatic cells shows potential for further examining the
pathogenesis of MPS IVA. With this technology, differentiation protocols could be used
to acquire desired cell types.
In this study, an iPSC model was established for MPSIVA as well as an
unaffected phenotype expressing pluripotency markers, rendering it capable for
differentiations. A direct and a progressive approach were taken for the differentiation of
iPSCs into a chondrogenic lineage. The direct differentiation of iPSCs into chondrocytes
was unsuccessful due to inconsistent results. An alternate indirect route through the
establishment of an intermediate mesenchymal stem cell (MSC) lineage before
chondrogenesis was then investigated and reached. With the MSCs, it was shown that
the severe disease clone not only has a decreased cell growth capacity, but also has
larger lysosomes and altered cytoskeleton structure, suggesting a clear phenotype that
could be altered upon treatment with rhGALNS. Furthermore, the MSCs can be loaded
with KS to recapitulate accumulation within the cell and levels are corrected to the
unaffected phenotype with rhGALNS. Thus a bioassay for measuring the intracellular
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activity of rhGALNS is introduced. Several attempts were made to further differentiate
the MSCs into chondrocytes, a difficult endeavor with varying results. The established
iPSC and MSC lines are a promising tool for the further development and understanding
of MPSIVA as well of a functional bioassay for rhGALNS using the natural substrate,
lumican, of the enzyme.
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I. Introduction
A. Goal of the Project
Due to the lack of patient material, appropriate cell model, or cell lines, further
work remains to be completed for the understanding of Morquio A. The goal of this
project is to: 1. Establish cellular disease models to study the pathophysiology of MPS
IVA using patient specific induced pluripotent stem cells; 2. Develop a functional
bioassay with established cellular model to measure intracellular rhGALNS activity.
Differentiation protocols will be explored and instituted for the derivation of patientspecific cell types, specifically chondrocytes, for the comparison of terminally
differentiated MPSIVA cells versus unaffected cells. Once the cell types are established,
we can investigate how different cell types are affected by MPS IVA and by treatment
with rhGALNS. The development of a bioassay will allow for the characterization of
biological drugs to demonstrate its ability to enter target cells and act on natural
substrates, an extremely useful tool for the biotechnology industry.

B. Background
B1. The mucopolysaccharidoses and Morquio A
The mucopolysaccharidoses (MPS) are a subset of inherited metabolic disorders
known as lysosomal storage diseases that are caused by a deficiency of specific
lysosomal

enzymes,

which

act

as

exohydrolases

in

the

degradation

of

glucosaminoglycans (Northover et al., 1996; Bielicki et al., 1995). In the case of MPS
IVA, the deficient GALNS enzyme hydrolyses the sulfate ester bonds of GalNAc6S and
Gal6S at the non-reducing termini of chondroitin 6-sulfate (CS) and keratan sulfate (KS)
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respectively (Bielicki et al., 1995). The partially degraded CS and KS accumulate within
the cells, causing interference with cellular function and excessive urinary excretion of
these glucosaminoglycans (Northover et al., 1996; Bielicki et al., 1995). The subsequent
cellular pathology is most prominent in connective tissues rich in KS, including cartilage,
cornea and heart valve. (Northover et al., 1996; Grande-Allen et. al., 2004; Dvorak-Ewell
et al., 2010). Other cell types, such as macrophages and coronary intimal smooth
muscle cells also contain excessive accumulation of GAGs, suggesting that the
pathophysiology may encompass non-KS-rich tissues (Dvorak-Ewell et al., 2010).
Morquio A, or MPS IVA, has a relatively high incidence rate compared to other
MPS disorders and does not involve the central nervous system, preserving normal
intellect (Bielicki et al., 1995; Northover et al., 1996; Montaño et al., 2007). Luis Morquio
in Montevido, Uruguay first described MPS IVA in 1929 when he observed four Swedish
siblings with skeletal dystrophy. James Frederick Brailsford also recognized similar
symptoms that same year in Birmingham, England. Since then, the knowledge of this
disorder has expanded greatly with a known occurrence rate of approximately 1 in
300,000. Patients are asymptomatic at birth and are usually diagnosed at around three
years of age after the evaluation for unusual skeletal features (Tomatsu et al., 2008).
Patients will typically undergo major surgical operations in the neck, hip, and leg regions
between the ages of 5-10 to improve the quality of life and be wheelchair-bound by the
time they are teenagers (Montaño et al., 2007).

Patients with severe forms of the

disorder do not typically live longer than the second or third decade of life due to
complications primarily related with cervical instability and pulmonary compromise
(Tomatsu et al., 2008).
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The lack of GALNS activity that causes this disorder affects the sequential
degradation and results in the progressive accumulation of GAGs in the lysosomes of
multiple organs, most apparent in the ligaments, connective tissues, and cartilage. MPS
IVA is characterized by: dwarfism, corneal clouding, progressive deafness, dental
abnormalities, joint laxity, muscular weakness, systemic skeletal dysplasia, heart valvular
disease, and mild hepatosplenomegaly (Bielicki et al., 1995; Tomatsu et al., 2007).
Additional compromised systems include the digestive, cardiovascular, and respiratory
systems (Northover et al., 1996). The broad spectrum of clinical phenotypes implies the
occurrence of several mutant alleles at the G6S locus (Bielicki et al., 1995). Currently,
patient care and treatment for MPS IVA include symptomatic management of skeletal
manifestations and the associated neurological and orthopedic complications associated
with the disease (Tomatsu et al., 2008; Hendriksz et al., 2012). Because of its relatively
high incidence rate and the lack of involvement of the central nervous system, MPS IVA
is ideal for the clinical evaluation of enzyme replacement therapy, which would move the
treatment of the disorder from symptomatic management to therapeutic intervention.

B2. Morquio Research- What’s Missing?
The above aforementioned facts infer that further research is needed on the
pathophysiology of MPS IVA. Certain limitations exist to conduct this research and
alternative methods should be considered. Firstly, an appropriate animal model has yet
to be proven for the study of MPS IVA. Using mice, it is possible to create a model with
no GALNS activity, but it has been shown that growth plate KS does not accumulate
(Montaño et al., 2008). Furthermore, visceral storage of GAGs other than KS was
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discovered in a model that unfortunately lacked the skeletal features (Tomatsu et al.,
2003). Therefore the human skeletal deformities typical of this disease are not
recapitulated in the murine models. These mice had undetectable KS levels in the urine
and serum and also failed to show GAG storage in cartilage cells, indicating clear
differences to the human phenotypes. Interestingly, the murine model does suffer from
substrate accumulation in the brain (Tomatsu et al., 2003; Tomatsu et al., 2008). Indeed
there are clear differences in the synthesis and distribution of KS in human and murine
tissues (Tomatsu et al., 2003). For example, two forms of KS, KS I and KS II, are found
in the cornea and skeleton of humans, respectively. However, the synthesis of KS II of
most tissues is much lower in rodents compared with humans and most other animal
species (Venn et al., 1985). Moreover, rodents do not have KS chains in the
proteoglycan aggrecan while other mammals do. This absence of KS II could explain
why MPS IVA mice have no skeletal clinical phenotype (Tomatsu et al., 2008).
Secondly, appropriate cell lines and available patient-specific material are very
limited and difficult to obtain for classical in vitro models. MPS IVA patient dermal
fibroblasts are accessible, but do not accumulate KS or display any pathology (Hollister
et al., 1975; Dvorak-Ewell et al., 2010). Other cell types such as chondrocytes isolated
from patients accumulate endogenously produced KS and can display variability
(Dvorak-Ewell

et

al.,

2010).

And

when

grown

in

monolayers,

chondrocytes

dedifferentiate and no longer express chondrocyte markers such as Collagen II and
Aggrecan (Gosset et al., 2008), and express an increased level of Collagen I (De
Franceschi et al., 2007). It can be concluded that the reduced ankle and joint movement
observed in MPSIVA patients may not only be due to proteoglycan accumulation, but
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also the high amount of collagen type I and the low levels of collagen type II fibers in
chondrocytes (De Franceschi et al., 2007). In MPS IVA, growth plate chondrocyte
pathology is characterized by vacuolar distention and poorly calcified matrix amongst
other manifestations. Furthermore, chondrocytes in the articular cartilage are vacuolated,
disorganized and show altered expression of extracellular matric component (Anderson
et al., 1962; McClure et al., 1986). In contrast, osteoblasts and osteoclasts appear
unaffected and histological studies confirm that bone tissue in MPS IVA is qualitatively
comparable to unaffected bone (McClure et al., 1986).
The use of human MPS IVA chondrocytes as a model was shown to be adequate
in testing enzyme replacement therapy with recombinant human GALNS (rhGALNS)
(Dvorak-Ewell, 2010). In this study, it was concluded that the MPS IVA chondrocytes
uptake rhGALNS into the lysosomes and that rhGALNS reduces KS accumulation and
can restore function to MPS IVA cells. However, this model has many disadvantages
that make further studies challenging- such as difficulty to maintain the chondrogenic
phenotype and a limited number of cells. Also, the MPS IVA primary human
chondrocytes were from iliac crest biopsies whereas the control unaffected chondrocytes
were isolated from healthy articular knee cartilage, making comparisons difficult due to
different origin. Further studies need to be conducted using an abundant source of MPS
IVA chondrocytes.
Moreover, there is a need for an in vitro functional bioassay for rhGALNS to
measure its intracellular activity on a natural substrate, lumican. Lumican is one of the
major KS-containing proteoglycans expressed in a variety of tissues and belongs to the
family of small leucine-rich repeat proteoglycans, which constitute an important fraction
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of non-collagenous extracellular matric proteins (Nikitovic et al., 2008). Natural substrate
bioassays are used in product comparability and characterization studies to demonstrate
its functionality. For the characterization of biological drugs, the regulatory expectation is
to have a functional bioassay available that ‘‘describes the specific ability or capacity of a
product to achieve a defined biological effect (Pungor et al, 2009; ICH Q6B
Specifications, 1999).” Such bioassay would be a great asset to biotech industries
launching a new product, as BioMarin Pharmaceutical is doing.

B3. Enzyme Replacement Therapy for Morquio A
BioMarin Pharmaceutical’s proposed treatment for MPS IVA is enzyme
replacement of GALNS through the production of recombinant human GALNS
(rhGALNS), intended to clear keratan sulfate from the lysosome. As reported by DrovakEwell et al., rhGALNS was produced from conditioned media from Chinese Hamster
Ovary cells stably overexpressing GALNS and sulfatase modifying factor 1 (SUMF1),
which is required for activation of all sulfatases. Previous reports were confirmed of the
association of rhGALNS as a non-covalent dimer in solution and as a purified enzyme
consisting of a major species of ~55 kDa, a minor species of ~40 kDa, and a species of
~19 kDa under reducing conditions (Masue et al., 1991). It was also shown that the
enzyme deficiency of MPS IVA fibroblasts was corrected upon addition of rhGALNS in a
dose-dependent manner and that rhGALNS uptake was mannose-6-phosphate (M6P)
receptor-dependent. Thus it was concluded that abnormal gene expression could be
improved upon treatment with rhGALNS, suggesting enzyme replacement therapy will
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not only reduce lysosomal storage, but also possibly restore normal cellular physiology
(Drovak-Ewell et al., 2010).
Currently, BioMarin Pharmaceutical’s GALNS for MPS IVA, or Vimizim, achieved
its primary endpoint in the phase 3 trial, confirming the efficacy of the enzyme
replacement therapy. Phase III clinical trials showed endurance improvements, clinically
meaningful improvements in two measures of endurance (6-minute walk distance and 3minute stair climb), and decreased urinary levels of keratan sulfate (BioMarin
Pharmaceutical Inc., 2012). These results are very promising, and the company is
beginning market applications to make the product available for patients. However, there
are still many questions to answer regarding the pathophysiology of MPS IVA, and a
cellular model would allow for further studies and serve to test therapeutic efficiency.
Using an in vitro iPSC-based model, differentiated cells will help understand MPS IVA
pathogenesis through the study of KS accumulation on chondrocyte differentiation and
gene expression amongst others, as well as the effects on cells upon treatment with
rhGALNS. If a cell model is accomplished, the development of a natural substrate
bioassay would benefit additional comparability and characterization studies to come.

B4. An Induced Pluripotent Stem Cell Model
We proposed to create an induced pluripotent stem cell-based model to continue
studies on the pathophysiology of MPS IVA. Through molecular reprogramming of
patient fibroblasts, the generation of diseased and unaffected cell lines has potential in
deciphering what remains unknown of this disease. The genetic reprogramming of adult
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cells creates an embryonic stem cell-like state where cells are forced to express genes
and factors to maintain pluripotent properties. Pluripotent stem cells can differentiate into
all three germ layers: ectoderm, mesoderm and endoderm, which can give rise to all cell
types of the body (Lanza, 2009). In 2007, it was shown that iPSCs were obtainable from
human somatic cells (Takahasi et al., 2007; Yu et al., 2007). The generation of iPSCs
has shown to be a breakthrough technology that has great therapeutic potential and
could be used for clinical applications.
Since iPSCs can be generated from patients using various tissues, they can be
used to obtain cells and progenitors carrying a disease-specific trait and to investigate
the impacts of this trait on the disease’s phenotypic development (Choi et al., 2011).
They can also possibly provide an unlimited supply of cells for drug testing. iPSCs are
morphologically similar to embryonic stem cells (ESCs), express pluripotency markers,
and also contribute to germ line transmission (Yamanaka, 2009). Because they have
pluripotent differentiation potential into committed functional lineages, iPSCs are a
valuable asset for the modeling of human diseases (Vitale et al., 2011). This is especially
relevant to creating an in vitro model to study MPS IVA pathogenesis, since there is no
applicable cell lines or available patient-specific material, rendering such studies difficult.
Using this technology, it would be possible to create in vitro MPS IVA models
through the differentiation of iPSCs to relevant cell types such as chondrocytes,
macrophages, myocytes, osteoblasts and osteoclasts for the comparison of normal
versus diseased lines. This would allow for the comparison of gene and protein
expression profiles as well as the effect on cells upon treatment with rhGALNS.
However, the differentiation into such cell types is time-consuming and has yet to be
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proven with iPSCs. It has been shown successfully with ES and human pluripotent stem
cells using various methods.

C. The Direct and Progressive Differentiation of a Chondrogenic Lineage
C1. Direct Chondrogenic Differentiation
Clinically relevant tissues or cell types are of utmost importance in the elucidation
of the extensive pathophysiology in MPS IVA. As Drovak-Ewell et al. demonstrated, the
therapeutic enzyme GALNS penetrates through even poorly vascularized tissues, such
as growth plate cartilage. Therefore, of particular interest to MPS IVA are chondrocytes,
cells that primarily make up cartilage and that produce/maintain the cartilaginous matrix,
which consists mainly of collagen and proteoglycans. As described in Section I-B3,
growth plate chondrocyte pathology in MPSIVA has many complications and setbacks
that demonstrate the importance of these cells in the disease. A steady, reliable
chondrocyte cell line would be of interest to scientists for further studies.
Direct chondrogenic differentiation has reportedly been achieved with human
embryonic stem cells through techniques such as high-density micromass culture (Figure
1). Ferrari et al. (2011) reports culture systems and conditions based on the progressive
and uniform differentiation of embryonic limb bud mesenchymal cells into chondrocytes.
Through such culture systems the close juxtaposition and subsequent cell-to-cell
interactions required for chondrogenic differentiation are recapitulated. Differentiation is
promoted with exogenous supplementation of pro-chondrogenic factors such as BMP-2
and TGFβ1, which are typical in vivo (Ferrari et al., 2011). Similarly, Gong et al. report
the same technique in which hESCs undergo direct, rapid, progressive, and substantially
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uniform chondrogenic differentiation in the presence of BMP2 alone or a combination
with TGFβ1. A second technique commonly used is a pellet culture (Figure 1), where
cells are cultured as a 3-dimensional environment allowing for cell-to-cell interactions.
This technique will be later explained in detail.

C2. Progressive Chondrogenic Differentiation
C2.1. Intermediate Mesenchyme Lineage
An alternative technique to consider in the differentiation of chondrocytes is an
indirect, intermediate mesenchyme progenitor lineage, which could circumvent the
challenges observed with direct differentiation of iPSC protocols. Mesenchymal stem
cells (MSCs) are not only tissue-specific adult stem cells that can be used for clinical
applications, but can also be further differentiated to other cell types. These multipotent
stem cells have a high capacity for self-renewal and can potentially differentiate into
osteoblasts, adipocytes, chondrocytes, or myocytes in vivo and in vitro (Asakura et al.,
2001; Mahmood et al., 2010). It was shown that these cells recruit from the perivascular
niche representing a tight network throughout the vasculature of the body (Crisan 2008).
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The characterization of MSCs is ambiguous and the defining markers are
inconsistent among investigators. A thorough literature research conducted by Mafi et al.
(2011) as well as additional published articles reveals the most commonly reported
positive markers are CD105, CD90 (THY-1), CD44 (HCAM), CD73, CD29, and STRO-1
(See Table 1). The most commonly reported negative markers are CD34 and CD14,
both cell surface markers absent on mesenchymal stem cells. Furthermore, the
Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular
Therapy proposes minimal criteria to define human MSC populations. MSCs must be
plastic-adherent under standard culture conditions, express CD73, CD90, and CD105,
and lack expression of CD11b, CD14, CD19, CD34, CD45, CD79α, and HLA-DR
surface molecules (Dominici et al., 2006). There is variable expression of the reported
MSC surface markers, which could be accounted for by different stages during cell
proliferation, the isolation and derivation of cells, and culture where the markers have
been accessed (Mafi et al., 2011).
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Adult stem cells have certain factors that limit their clinical use however, such as
insufficient number of cells from tissue biopsies, impaired growth, and poorly defined
phenotype (Mahmood et al., 2010). Therefore using iPSCs to obtain adult stem cells
would potentially create a source of unlimited, pluripotent lineage-specific cells. Many
protocols have been reported for the derivation of MSCs, and this study will highlight the
three protocols that were attempted.
Mahmood et al used the embryoid body formation technique efficaciously to
directly differentiate human ES cells into mesenchymal progenitor cells (Figure 2). This
team demonstrated that paraxial mesodermal markers and myogenic development
markers were markedly upregulated with the inhibition of transforming growth factor β
(TGF-β) signaling using a small molecule inhibitor SB-431542 (SB) in serum-free
medium. This inhibition enhances expression of mesodermal lineage marker genes and
can promote cardiomyogenesis. The continuous inhibition of TGF-β enriched myocyte
progenitor cells in EB outgrowth cultures. This myogenic lineage further differentiated
into mesenchymal progenitors by the inhibition of the TGF-β signaling pathway
(Mahmood et al., 2010).
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Another technique is described by Stavropulos et al for the derivation of
multipotent mesenchymal precursors from human ES cells through the culture of the
cells at low density with chemically defined serum-free medium. The hESC colonies
were seeded on murine embryonic fibroblasts (MEFs) in the serum-free media, which
induced the cells to adopt an endomesodermal fate and a subsequent mesenchymal
phenotype. This technique is fairly simple and consists of a 3-week differentiation period
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followed by a 1-week expansion period.

As can be seen below, the results are

multipotent mesenchymal precursors with osteogenic, chondrogenic, adipogenic, and
myogenic potential (Stavropoulos et al., 2009).
In addition, Oldershaw et al.’s protocol for the direct differentiation of hESCs into
chondrocytes reports that mesodermal cells appear at the second stage, day 9 of
differentiation. Cells are directed through intermediate developmental stages using
substrates and chemically defined media supplemented with exogenous growth factors,
progressing through primitive streak or mesenderm to mesoderm before the
chondrocytic stage. The full protocol has previously been attempted in the laboratory
unsuccessfully for chondrocytes. It would be of interest to attempt this mid-way
differentiation to obtain MSCs. Upon accomplishment of attaining CD73+ progenitor
cells, further culture of cells is conducted followed by demonstration of the characteristic
phenotypes of MSCs, especially the expression of specific genes (See Table 2).
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C2.2. The Chondrogenesis of MSCs
The differentiation of MSCs into chondrocytes is not only a promising alternative
for the regeneration of cartilage but also for a stable supply of chondrocytes that can be
used for disease modeling. Many culture methods have been reported, especially highdensity cell cultures such as the micromass and pellet techniques. This study will focus
on the pellet culture, which provides a three-dimensional environment that allows cell-tocell interactions similar to those observed in vivo during embryonic developments (Zhang
et al, 2010). It has been reported that MSC’s are capable of chondrogenic differentiation
in pellet culture using serum-free medium and transforming growth factor β family
(Johnstone et al. 1998). Other protocols involve media containing FBS or commercial
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kits with media containing reagents for inducing the commitment of MSCs into the
chondrogenesis pathway. For example, Gibco’s STEMPRO® medium provides a
standardized culture workflow solution for the culture of MSCs and ultimate derivation of
chondrocytes. A modified protocol containing serum-free, serum media, or commercial
media will be conducted for the establishment of a differentiation protocol to use with
MSCs. After all experiments, characterization of pellets will also be conducted for
chondrogenic markers. Gene expression will be carefully examined with the natural
niche of chondrocytes in mind where different layers of the growth place express genes
that are specific to the cell type (Figure 3)
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D. Summary
Morquio A Syndrome, or MPS IVA, is a lysosomal storage disorder involving an
extensive pathophysiology with multiple organs and manifestations. The broad range of
clinical characterizations in patients and the lack of an animal model implicate a need for
further understanding of the pathophysiology of MPS IVA. Currently, there is no
applicable animal model or appropriate cell lines and available patient-specific material is
very limited and difficult to obtain for classical in vitro models, rendering the study of the
systemic pathophysiology of MPS IVA challenging and limited. Thus, the generation of
an induced pluripotent stem cell (iPSCs) line from patient-specific somatic cells is a
promising alternative for studying the pathogenesis of MPS IVA, which is what we do in
this study.
Using iPSC technology, differentiation protocols can be used to acquire certain
cell types, such as a chondrogenic lineage. Challenges to this goal include unestablished protocols for iPSC differentiation to follow and the amount of time it takes to
differentiate each line. However, once the cell types are acquired, many disease-related
factors can be compared, as well as the effects of recombinant human GALNS
(rhGALNS) treatment. With this in vitro model, an in-depth study of the pathogenesis of
MPS IVA is possible as well as the development of a functional bioassay for rhGALNS.
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II. Materials and Methods
A. Direct Differentiation of iPSCs into Chondrocytes
A1. iPSC Culture
Normal fibroblasts and two MPSIVA (moderate and severe disease) patient
fibroblasts were obtained and reprogrammed using retroviruses encoding human
transcription factors Oct4, Sox2, Klf-4, and c-Myc by Andrzej Swistowski in the laboratory
(Figure 4). The lines were maintained undifferentiated using either a feeder culture or a
feeder free culture. For the feeder culture, iPSC colonies were maintained on primary
mouse embryonic fibroblast feeder cells (PMEF-CF, Millipore) seeded at appropriate cell
density in plates precoated with gelatin (0.1%, Millipore). Cells were cultured with ES
medium containing DMEM/F12 (Invitrogen), 20% Knockout Serum Replacement (KSR,
Life Tech.), 200mM Glutamax (100X, Life Tech.), Non-essential Amino Acids(NEAA,
100X, Life Tech.), 2-mercaptoethanol (1000X, Life Tech.), and 25µg/ml bFGF2
(10µg/mL, Life Tech). Media was changed daily after the first 48 hours in culture and
splits were conducted enzymatically with collagenase IV (Life Tech., 1mg/mL) every 4-5
days. Feeder-free cultures were used when single iPSC colonies were needed without
interaction of feeder cells. iPSC colonies were plated on alternate growth substrates
such as Matrigel of Geltrex (Life Tech.)- coated plates, cultured with pre-conditioned ES
medium and medium changed every alternate day.
Characterization

of

derived

iPSCs

was

done

initially

through

immunocytochemistry for pluripotency markers and karyotyping for verification of any
chromosomal abnormalities. Pluripotency markers Oct4, Tra 1-60 and Tra 1-81 were
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also periodically checked to verify that cells remained pluripotent through passages (See
ICC Technique).

A2. Differentiations
Pellet Culture
Using a protocol that was modified accordingly by Andrzej Swistowski, iPSCs
were exposed to a pellet technique for the differentiation of chondrocytes. Colonies of
cells were harvested and directed towards a single-cell suspension using accutase. Cells
were resuspended in chondrogenic medium (DMEM Hi Glucose, 1% ITS, 40ug/ml Lproline, 1% Sodium Pyruvate, 1% NEAA, 1X PenStrep, 50ug/ml ascorbic acid, 10-7M
Dexamethasone, 10ng/mL TGF-β1, and 100ng/mL BMP-2) as a 1 million cell/pellet or

	
  

20	
  

0.5 million cell/pellet mixture and spiked with ROCK inhibitor to avoid cell death. Cell
mixture was placed in a 15-mL canonical tube with the tube cap slightly unscrewed to
allow oxygen exchange and incubated overnight. Pellets form overnight and media was
changed every alternate day for 21 days.
Micromass Culture
A modified micromass culture system was used as previously described (Mello et
al. 1999; Toh et al. 2010). iPSCs of each clone were harvested and resuspended in
chondrogenic medium (DMEM Hi Glucose, 1% ITS, 40ug/ml L-proline, 1% Sodium
Pyruvate, 1% NEAA, 1X PenStrep, 50ug/ml ascorbic acid, 10-7M Dexamethasone, and
10ng/mL TGF-β3). 5X105 cells were carefully placed, or “spotted” in the middle of 24-well
plates as droplets and allowed to adhere for 2 hours in incubator. An additional 500ul
medium was carefully added after this incubation period and allowed to form spheres
overnight. Medium was changed every 3 days with fresh factors for the 14-day
differentiation period.

B. Indirect Chondrocyte Differentiations
B1. Establishment of Intermediate Mesenchymal Lineage
B1.1. Embryoid Body Technique
For the derivation of mesenchymal progenitor cells, the first technique used is an
EB outgrowth culture treated with a small molecular inhibitor as previously described by
Mahmood et al. Normal and severe clone iPSCs were harvested using collagenase IV
and fragmented into small clumps for the formation of embryoid bodies. Clumps were
placed in a low-adhesion petri dish on a rocker to avoid settling or attachment to plate in
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ES medium supplemented with SB-431543 (10µM). Media was changed on days 3, 6,
and 8 by gravity sedimentation. On day 10, the EB’s were transferred to fibronectincoated (10mg/mL, Millipore) plates for EB-explant outgrowth culture. Chemically defined
medium

(CDM)

composed

of

DMEM/F12,

0.5%

BSA

(Fraction

V),

1%

Penicillin/Streptomycin, 10% Insulin-Transferrin-Selenium (ITS), and SB-431543 (1mM)
was used to allow for cellular outgrowth and the formation of a cell monolayer. The
outgrowth culture was allowed to grow to confluency, at which time subsequent
passaging was performed using accutase to reach a single-cell mixture. Cells were
plated on uncoated cell culture dishes or flasks in CDM medium. After 2-4 passages,
cells were transferred into MSC medium for further growth. When cells expanded to 2-3
T175 flasks, magnetic bead (FACS) sorting was performed.
B1.2. Low Density Culture
A modified protocol as reported by Stavropoulos et al. was followed for the
derivation of multipotent mesenchymal precursors. A normal split of the iPSCs was first
done using collagenase IV and cultured as normal with ES media until colonies reached
appropriate size of 30-50cells. Medium was then switched to ITS medium containing
DMEM/F12, ITS supplement (Invitrogen), and Pen/Strep for Day 0 time-point. The
medium was replaced every 2-3 days with fresh ITS medium. At day 14, cells were
harvested using accutase and re-plated on 60mm fibronectin-coated dishes at a split
ratio of 1:3 with ITS medium. At day 21, cells were changed to MEM medium containing
alpha-MEM, 10% (v/v) heat-inactivated FBS (Invitrogen), 2mM L-glutamine, and 1X
Pen/Strep. Cells were cultured in this medium for an additional 7 days, changing media
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every 2-3 days. CD73+ cells were isolated through magnetic sorting and further
characterization followed after further culturing.
B1.3. Intermediate Development Stage
Oldershaw et al. (2009) reports a protocol for the differentiation of iPSCs into
chondrocytes with a mesodermal stage in between. This protocol what followed up to
this second stage for the derivation of MSCs using the severe and moderate MPSIVA
clones. A feeder-free culture of iPSCs was achieved with mTESR1 medium (Stem Cell
Tech.) and harvested with accutase to obtain a single cell suspension. A cell mixture
containing 2.1X106 cells was plated on 60mm cell culture dishes coated with fibronectin
in DMEM/F12 medium composed of 2mM Glutamax, 1% ITS, 1% NEAA, 2%B27, 90uM
B-mercaptoethanol, and appropriate factors according to paper. Passages were carried
out as cells became confluent. At day 9, cells were switched to MSC medium (alpha
MEM medium containing 10% FBS (Hy Clone) and 100X Pen/Strep) and subsequently
passaged on gelatin-coated culture dishes followed onto non-coated tissue culture
flasks. After four passages in MSC medium, cells were subjected to magnetic bead
sorting using CD73-PE antibody according to protocol (See Techniques Section II-D1).
After sorting the CD73+ cells were plated onto 100mm gelatinized culture dishes and
cultured with MesenProRS serum-free media (Invitrogen). Further characterization of
cells was done using flow cytometry and ICC.
B1.4. MSC Culture
The three lines of derived mesenchymal stem cells were banked and stored in
nitrogen until necessary use. When cultured, MSC’s were plated on cell culture flasks
and grown in MSC media or commercially available MesenProRS media. Cells were
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passaged every 3-4 days upon reaching 80-90% confluence with TrypLE using normal
cell culture techniques and media was changed every 2-3 days.
B2. Chondrogenic Differentiation of MSCs.
The differentiation of MSCs into chondrocytes is achieved using the pellet culture
system and exposure to 5ng/mL transforming growth factor β3 (TGFβ3; R&D Systems)
and 200M ascorbic acid (AA; Sigma) in MEM medium. The pellets are cultured for 3 to
four weeks with fresh media change every 2-3 days. Pellets were harvested at several
time points, washed with PBS, snap frozen, subjected to sonication using the Covaris
CryoPrep Cryogenic pulverizer for mRNA extraction (see Gene Expression Analysis).
Some pellets were also harvested for immunohistochemistry.

C. Treatment with rhGALNS
The MSCs were used to assess the therapeutic efficiency of rhGALNS and to see
effect of treatment on cells, specifically the growth rates. Treatment of cells was done
with 10 nM rhGALNS diluted in PBS + 0.1% BSA, typically for seven days. For the
negative controls or non-treated groups, cells were exposed to the formulation buffer of
GALNS at the same concentration to ensure that no other factors influences results.

D. Techniques
D1. Automated Cell Separation
Magnetic bead sorting of MSCs was done using the autoMACS® Pro separator
with CD73-PE antibody and Anti-PE MicroBeads (Miltenyl Biotech) according to
manufacturer’s instructions. After sorting, cell count and viability of cells was checked

	
  

24	
  

and cells were plated on con-coated culture dishes. Plates were carefully observed for
the attachment of cells, focusing on a fibroblast-like morphology typical of MSCs.
D2. Phenotypes Analysis by Flow Cytometry
The BD Accuri C6 flow cytometer was used for the verification of CD73+ cells with
the CD73-PE antibody used for cell sorting. Respective fibroblasts were used for each
clone as a negative control that does not express CD73+. MSC’s were first harvested
with accutase for single cell suspension and 2X106 cells re-suspended in FACS buffer
(PBS + 1% BSA). The mixture was split in half, one set use with the CD73-PE (MACS)
antibody and the second for the PE mouse IgG Control (BioLegend), both at a 1:20 ratio.
Tubes incubated with antibodies on ice for 30 minutes and an additional volume of FACS
buffer was added to each tube. After spin, supernatant was discarded and pellet was resuspended in FACS buffer for run on flow cytometer. Instructions according to
manufacturer were followed.
D3. Gene Expression Analysis (qRT-PCR)
Total RNA was extracted using the RNeasy Plus Mini Kit (Qiagen) with the tissue
sample protocol for iPSCs and MSCs. For chondrogenic pellets, the RNA extraction was
performed through the Trizol method according to the PureLink RNA Mini Kit (Ambion)
with PureLink DNase (Invitrogen) treatment for DNA-free RNA. A high-capacity cDNA
SuperScript® VILO™ (Invitrogen) kit was used for reverse transcription of 1µg RNA
according to instructions. cDNA was used for real-time PCR with the LightCycler 480
Real-Time PCR System (Roche), TaqMan Gene Expression Master mix, and TaqMan
Gene Expression Assays for SOX9, aggrecan, type II collagen (COL2), type X collagen
(COL10), and type 1 collagen (COL1) (see Table 1). A crossing point (CP) determined
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for each gene of interest, using a Second Derivative Maximum Method, was normalized
to the mean CP for Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in the same
sample.

D4. xCELLigence
Cell viability, size, and growth was monitored using the xCELLigence system
(Roche Applied Science), which uses 96-well plates containing inter-digitized
microelectrodes, for the noninvasive real-time monitoring of cells. Cells were first plated
at increasing densities to observe the optimal density and time point for experiments.
Cells were plated at appropriate densities and observed daily. Cell index was used as an
indicator for cell size and growth rate, increasing as time progressed. Experiments were
stopped once a plateau was reached on graph, indicating reduced proliferation.
D5. Immunocytochemistry
Cells were plated onto multi-channel glass slides or 24-well plates to proper
confluency and fixed with 4% PFA for 20 min followed by 3 washes with PBS. Cells were
then exposed to a second fixation with ice cold 90% methanol followed by 3 washes with
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PBS. Primary antibodies were diluted in a blocking solution containing 0.3% Triton X100, 10% goat serum, and 1% BSA and left on cells overnight at 4°C. Cells were then
washed 3-5 times with PBS and secondary antibodies then applied with blocking buffer
for 1 hour at room temperature in dark. Cells were then stained with Alexa-Fluor 488- or
Alexa-Fluor 594-conjugated Goat secondary antibodies (Life Tech). After incubation,
cells were washed again and slides mounted with ProLong Gold (Invitrogen) containing
DAPI for a counterstain of the nuclei.
For confirmation of pluripotency of iPSCs, the antibodies used were: TRA-1-60
(Millipore), a cell surface antigen of human embryonal carcinoma cells; TRA-1-81
(Millipore), a glycoprotein expressed on the surface of stem cells; and Oct4 (AbCam), a
transcription factor required for the sustainability of self-renewal and pluripotency of stem
cells.
For verifying mesenchymal lineage of MSCs, the markers used were: H-CAM
(CD44), a glycoprotein involved in cell-to-cell interaction and hematopoiesis; THY-1
(CD90), a glycoprotein cell surface antigen; STRO-1, a cell surface protein expressed
when cells are capable of differentiating into mesenchymal lineages; and MCAM
(CD146), a cell adhesion molecule used as a marker for endothelial cell lineage, all from
a characterization kit (Millipore). Additional proteins tested included: CD19 and CD14
(Millipore), hematopoietic markers not expressed by MSCs and thus used as negative
markers; CD73 (AbCam), a clear marker for MSCs; Vimentin (Millipore), a marker
belonging to the intermediate filament family and highly expressed in MSCs; and VCAM1 (Invitrogen), a member of the immunoglobulin family.
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D6. High Content Screening
Using the ImageXpress Micro XL system (Molecular Devices) and the Operetta
system (PerkinElmer), high throughput imaging was possible for automated widefield
and confocal imaging of the MSCs. Using a 96-well plate, MSCs were plated at
increasing cell densities to account for different growth rates and size of cells. Cells were
stained with Phalloidin for actin filaments as a whole cell body stain, LAMP-1 for
lysosomes, and nuclear DAPI. Fluorescent and brightfield imaging according to
manufacturer’s instructions was done to measure lysosomal content, cell size, and cell
shape/morphology of three clones.

III. Results
A. The iPSC Line
Fibroblast cell lines obtained from Coriell Cell Repositories were cultured for use:
a MPSIVA moderately attenuated line expressing 3% GALNS, a MPSIVA severely
attenuated line expressing less than 1% GALNS, and an unaffected healthy line.
Mutations were verified by activity assays and sequencing (data not shown). The
fibroblast lines were successfully reprogrammed into induced pluripotent stem cells using
retroviruses previously described in Section II-A1. The three clones were subjected to
long-term culture using mitomycin-C treated MEFs as stable colonies in the feeder based
system for over 40 passages and were able to generate high quality embryoid bodies
(Figure 5). Furthermore, both lines of MPSIVA iPSCs show normal karyotype.
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A1. Confirmation of pluripotency
Pluripotency was verified through immunostaining and the ability to form embryoid
bodies before beginning any experiment and at intermediate time points in culture
maintenance. This was done in order to confirm the retention of an undifferentiated state
as well as the potential of cells to differentiate into cells from all three germ layers:
endoderm, mesoderm, and ectoderm. All clones showed positive expression of iPSC
pluripotency markers OCT4, Tra-1-60, and Tra-1-81 (Figure 6). These expression
profiles verify the pluripotent cell populations and their ability to proliferate or
differentiate. Furthermore, pluripotency is also confirmed with formation of embryoid
bodies in vitro. Thus the iPSCs can be used to differentiate any cell type as long as
pluripotency is maintained.
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A2. Initial differences observed between clones
During maintenance of the iPSC culture, several observations were made that
suggest a clear difference in phenotype of the severe clone (Table 2). Overall, the
severe clone behaves better in the feeder-based culture as opposed to in feeder-free
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culture, though random spontaneous differentiation is at times observed. The unaffected
and moderate clones remained stable in this culture on the other hand. Manual
dissections of differentiating clones were done when necessary, which ensured the
maintenance of an undifferentiated state. The feeder-free culture of the severe clone was
difficult, with significant random spontaneous differentiation observed. Moreover, the
severe clone grows at a slower rate, requiring later passaging and harvests for
experiments. The unaffected and moderate clones behaved relatively the same.

B. Direct Chondrocytic Lineage
B1. Multiple attempts made
Using the high-density micromass culture, iPSCs were subjected to a direct and
uniform chondrogenic differentiation as reported by Mello and Toh et al. However, cell
spheres spotted on tissue plates only remained spheres for approximately 5 days.
Around this time, spheres flattened out and there was significant cell loss. Cultures were
still maintained until the allotted 14-day differentiation. As shown in figure 7A, there is a
relatively low expression of SOX9, a chondrogenic transcription factor, and of COL2, a
typical cartilage characteristic collagen at the day 14 time-point. COL2 and SOX9 are
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visible in the two samples and not in the negative control, suggesting chondrogenesis
was initiated. Similar observations were made with the pellet culture (not shown), in
which pellets lasted approximately 8 days before flattening out or dissociating.
Expression of COL2, however, was lower in pellets whereas the expression of SOX9
remained similar. COL1 was seen at high levels in both techniques, suggesting latestage chondrocytes gearing towards a bone-like step. No expression of aggrecan was
seen in any samples. The ICC of pellet samples (Figure 7B) shows positive staining of
COL2 and negative staining of Aggrecan, since stainings are weak and non-specific,
rendering results inconclusive. Several rounds of each differentiation were conducted in
which results remained similar, even when supplemented with recombinant human Acid
Ceramidase (rhAC), which was thought to facilitate the generation of chondrocytes with
enhanced quality and expression of markers. Thus a new approach was necessary for
the derivation of chondrocytes.
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C. Indirect Chondrocytic Lineage
C1. MSC Line Established
To circumvent the challenges observed with the direct differentiation of
chondrocytes from iPSCs, creating an intermediate mesenchyme progenitor lineage was
investigated through several protocols. The differentiation of MSCs from iPSCs has been
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reported in many techniques, three protocols were used: 1) EB-outgrowth, 2) Low
density, and 3) Oldershaw. The EB-outgrowth protocol in which cells are cultured with
the SB-431542 inhibitor proved the most efficacious. EB’s of 3 clones were cultured for
10 days with no issues, at which time an outgrowth culture was set up on fibronectin- or
gelatin-coated plates. EB’s attached and formed a monolayer better on the fibronectincoated plates. Interestingly, the moderate MPSIVA clone EBs did not attach as well
overall, and dissociation of EB’s was observed the following day, suggesting extensive
cell loss. On approximately day 17 of experiment, beating colonies were observed for all
three clones- most likely an intermediate myocyte stage- that lasted 2 days. Following
several splits when confluency was reached, the moderate clone saw an increased cell
loss. At the time for sorting, there were not a sufficient number of cells for this clone and
was thus not used. The CD73+ sorting of normal and severe MPSIVA clones was
successful and resulted in good cell yield, rendering expansion possible for banking and
characterization.
The second technique used was the low-density culture of small iPSC colonies
seeded on MEFs and treated with ITS in chemically defined media. At day 7 of
experiment, differentiation was observed first in the moderate and severe clones, with
expansion of colonies and a morphological change of outer cells. 3 days later, MEFs
begin lifting off and many dead cells are observed, an observation which progressively
worsens as days pass. To avoid further cell loss, plates were switched to MEM media at
day 12, which appeared to alleviate the issue of cell loss. At the allotted 14-day period,
cells were split according to protocol and re-plated on fibronectin-coated dishes. After
second split, the normal and moderate clones had few colonies/ cells that attached
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whereas the severe clone had many. At the end of the experiment, only the severe clone
remained with sufficient cells for the CD73+ cell sorting. The FACS sorting for CD73+
cells was successful and the clone was expanded and banked.
The third technique used was the Oldershaw protocol that reports a mesodermal
stage during differentiation of iPSCs into chondrocytes. Protocol was followed up to this
second stage for the moderate clone, since others had already been acquired and due to
time constraints. Differentiation occurred during a 9-day period in which time various
factors were added according to protocol. A high proliferative rate was observed and
there was a sufficient amount of cells at the end for sorting. Sorting resulted in a decent
CD73+ yield, which was expanded for banking and characterization. Thus, the
mesenchyme progenitor lineage was reached for the three clones using different
protocols: the unaffected line was established using the EB-outgrowth protocol, the
moderate line was established using the Oldershaw protocol, and the severe clone was
established using the EB-outgrowth as well as the low density protocols- but the EBoutgrowth cells will be used for experiments.
C1.1. Characterization and differences in clones
To verify the mesenchyme lineage, sorted cells were subjected to various
characterization protocols. The first characterization was a flow cytometric analysis with
the CD73 antibody used in cell sorting conjugated to a fluorescent probe. As shown in
figure 8, each clone shows a clear shift from the IgG isotype control, verifying the
expression of CD73 cell surface marker typical of MSCs. This shift is not observed in the
negative control since iPSCs do not express CD73, rendering iPSCs an adequate
negative control.
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Next, a qualitative real-time analysis was performed on the unaffected and severe
MSC clones with 5 genes reportedly expressed by MSCs (recall Tables 1 and 2):
CD105, CD44, CD73, CD29, and THY-1 (CD90). Undifferentiated unaffected iPSCs
were used as a negative control for all markers. However, positive expression of THY-1
is seen for iPSCs, and research shows it is a common marker for various stem cells.
Thus iPSCs are not an adequate negative control for this marker. CD29, an integrin
family glycoprotein, and CD44 (HCAM), a cell surface glycoprotein, are both expressed
at relatively high levels (Figure 9A) in both unaffected and severe MPSIVA clones
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compared to the other genes. Interestingly, 4 out of the 5 markers have higher
expression in the unaffected clone except for THY-1. When calculating percent control
with the unaffected clone set at 100% (Figures 9B, C), we see that the moderate clone
expresses almost double the level of THY-1 and almost the same level of CD105.
Interestingly, these two markers are the lowest expressed in the severe clone.

Lastly, immunofluorescent stainings revealed positively stained cells for MSC markers
CD73, Vimentin, STRO-1, and HCAM (Figure 10). The negative control markers CD14
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and CD19, expressed in macrophages and lymphocytes respectively, were not
expressed in any cells. Stainings for VCAM (not shown), a cell surface protein,
repeatedly showed nuclear staining, consistent with the gene expression data which
showed no expression of VCAM, suggesting unspecificity of marker or its absence in our
MSCs. As a negative control for makers, undifferentiated iPSCs were also stained and
demonstrated negative expression of all markers. These immunofluorescence data
demonstrate the differentiation of iPSCs to MSCs and expression of cellular markers
known to be associated with MSCs.

	
  

38	
  

Upon culturing the MSCs for banking and characterizations, some initial
differences were observed between the three clones. It was apparent early on that the
severe MPSIVA clone grows slower than the other two clones- which was also observed
in the iPSC culture. As can be seen in the images from figure 10, there are some
morphological differences observable between the moderate and severe MPSIVA clones
(Figure 10). The moderate and normal clones behave similarly, and both cell populations
have a fibroblast-like morphology whereas the severe clone is a bit different. These
observed differences initiated new questions and experiments to better understand the
cell types and whether these observations could be disease-specific.
C1.2. Growth Rates Investigated
Upon noticing these changes in the MSC culture, several experiments were
conducted to check growth rate and confluency. Cell diameter and cell circularity were
regularly checked during each passage before beginning any experiment, and it
appeared that the severe MPSIVA clone has a larger diameter for the most part (Table
3). At times, the diameter decreases, which could be due to cellular stress or confluency.
A quick experiment using the CloneSelect Imager, which allows us to monitor cells and
identify densities as well as cell number estimates, demonstrated that normal and
moderate MPSIVA cells indeed grow faster and mostly uniformly, as shown by
increasing confluency percentages with time (Table 3). The severe MPSIVA clone shows
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a decreased growth rate as confluency is reached at later time points and can remain at
the same density for several days.

C1.3. Treatment with rhGALNS
After initial confirmation of these preceding observations, it became of interest to
see if the growth rate would be altered or rescued upon treatment with rhGALNS,
especially for the disease clones. Using the xCELLigence system, a real-time monitoring
of cells was possible where cells are measured for confluency (and thus growth rate),
viability, and morphology. Several experiments were set up with treated and non-treated
groups of cells for comparison to test the effect of treatments on cells in terms of growth
rate and cell size. As previously observed, the severe MPSIVA clone did not proliferate
until day 6, at which time the treated group saw a dramatic increase. However, the
curves in the graph suggest a positive effect of GALNS in all clones, even in the
unaffected clone though not as high (Figure 11A). The slope of the curves is highest in
the moderate and severe clones after about 4 days, at which time there is a clear
increase between the two treatments (Figure 11B).
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Further attempts were made using the same set-up with a longer period of time to
confirm these results. Figure 11C shows the previously stated increase in slope for the
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severe MPSIVA clone only. The unaffected clone had a slight shift in curve but the slope
remains the same between the two treatment groups. The moderate clone remains
stable with no clear shifts. At approximately day 10, all clones see a dramatic decrease
in slope, most likely due to confluency, stress, or culture conditions. Interestingly, as can
be seen in figure 11A, the severe clone has the lowest cell index at the end of the
experiment at 200 hours. However, in the second experiment (Fig 11C), we see that at
300 hours, the severe clone is now at a higher cell index than the other two clones.
Additionally, the severe clone’s slope continues to increase after the other two have
reached a plateau, an indication that cells have reached full confluency and begin to die
off. These results initiated further questions regarding the size and specificity of our cell
line, especially in terms of the cell index. It could be that we are seeing the higher index
in the severe clone because of the difference in cell size, or perhaps accumulation within
the cell. Since cell index is only a relative measurement, it is of interest to further
investigate differences between three clones, especially cell size.
Cells were also plated for Immunostaining and demonstrated that rhGALNS
trafficked to lysosomes, as evident by its colocalization with LAMP-1 (Figure 12). High
content screening demonstrated 98% colocalization of rhGALNS and LAMP-1 granules.
Previous work by Drovak-Ewell et al. (Figure 13A) showed that addition of rhGALNS to
MPSIVA fibroblasts corrected their enzyme deficiency dose-dependently. rhGALNS
uptake was M6P receptor-dependent (Figure 13B), since it was significantly inhibited by
M6P. These findings were further supported and re-capitulated by these results using
MSCs.
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Additionally, the three MSC clones were cultured for 7 days with and without
rhGALNS treatment to test for keratan sulfate accumulation and reduction. Using
capillary electrophoresis analysis, a technique used to analyze GAGs, no detectable KS
or CS levels were found in any sample (data not shown). The experiment was repeated
with the addition of aggrecan, a proteoglycan with CS and KS chains attached to the
protein core, to see whether cells could accumulate KS. Cells were immunostained with
LAMP-1 and KS for analysis. KS did accumulate and was 99% co-localized to the
lysosome. As can be seen in figure 14, there was an increase in KS granules in the
moderate and severe clones which was reduced to the unaffected levels upon rhGALNS
treatment.
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C1.4. The search for phenotypic differences
Using the technology offered by high content screening, an in-depth analysis of
cells is possible. To confirm the growth rate hypothesis, the three clones were cultured
for 3 days beginning with the same number of cells. After this time, brightfield imaging
was done and cells counted. As previously shown, the severe clone has the least
number of cells with normal and moderate clones close together. Next, clones were
stained with phalloidin for a whole cell body stain and LAMP-1 for investigating
lysosomal content (Figure 15A). These initial stainings demonstrate a possible difference
in cell size, with the unaffected clone appearing smaller and thinner. Moderate clone
appears slightly larger than the unaffected clone, and the severe clone is the largest.
Furthermore, the moderate and severe clones show an increased filamentous phenotype
as well as an increase in lysosomal content/size. Analysis of the LAMP-1 staining was
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done by calculating the total area of granules per site (mean granule area) and
confirmed the observation of increased lysosomal content in the severe clone, with the
highest area compared to normal and moderate clones (Figure 15B). The analysis of
LAMP-1 spot intensity also showed the highest mean in the severe clone, with moderate
clone close behind. (Figure15C). These results indicate possible phenotypic differences
amongst the three MSC clones, and it is of interest to investigate the filamentous
composition of the cells as well as the lysosomal content. These observations could
possibly change upon treatment with rhGALNS, especially the increased lysosomal
content of the severe clone. Repeat and further experiments are necessary to further
examine these phenotypes.
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C2. The chondrogenesis of MSC’s
C2.1. Characterization and differences in clones
After the successful derivation of MSCs, a chondrogenic lineage can be explored
through differentiation protocols followed by characterization. Using the pellet technique,
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several rounds of differentiations were done under various conditions. A consistent
protocol according to Section II-B2 was followed for all the differentiations to ensure
accurate comparisons. The first differentiation was done with the unaffected clone for 25
days with harvest points every 5 days. No specific problems were encountered during
this experiment, with well-formed pellets that remained consistent for the whole period.
As shown in figure 16A, Col2 and aggrecan show a similar expression pattern where the
levels peak at day 20 before decreasing once again. In comparison, Sox9 and Col10
expression is relatively low (Figure 16B, C). However, these two markers also show a
similar expression pattern where the highest expression is seen on day 15, 5 days
before Col2 and aggrecan. It is of interest to observe expression levels of markers at
later time points of the differentiations, especially for Col2 and aggrecan, whose
expression is still relatively high at 25 days. The expression of chondrogenic markers
might change at day 30 in a positive of negative manner. Due to these initial results, this
protocol seems promising compared to the direct chondrogenic differentiations
previously attempted and described in Section II-A.
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Ensuing these results, the same protocol was done with the moderate and severe
clones to see if the expression of markers changes or if these clones will withstand the
differentiation period. Initially, it was observed that the severe clone pellets were bigger
after several days in culture, even though pellets begin with the same number of cells.
Furthermore, the severe pellets were more flat whereas the moderate clone pellets
remained round, although smaller in size. As the harvest time points progressed, the
nucleic acid concentration of the moderate clone decreased each time, suggesting
possible cell loss with smaller pellets. There was an overall high expression of Col10 in
both clones, and the expression pattern was similar to Sox9 (Figure 17A). However, Col2
expression was low compared to positive control and there was little to no aggrecan
expression observed, especially in the severe clone. For the moderate clone, the
expression pattern of aggrecan and Col2 was equivalent. There was no aggrecan in
severe clone, though it had higher overall expression of Col2 (Figures 17B, C).
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After these rounds of differentiations, some morphologic observations were made
in the pellets that portrayed a similar pattern in each case. There were several apparent
differences between the three clones in the pellet form. As shown in figure 18, the size of
the pellets vary, with severe clone being the biggest and moderate clone the smallest.
Furthermore, the severe pellets seem to flatten out more as time progressed. There was
also some dissociation observed at times, especially in the moderate and severe clones
when compared to unaffected. Some experiments were done to test the effect of hypoxic
conditions on the clones’ differentiation. Hypoxic conditions are described as increasing
the expression of chondrogenic markers by mimicking the poorly vascularized growth
plate (Recall Figure 4). A serum-free media and a special chondrocyte commercially
available media were also tested to try to ameliorate the chondrocyte differentiation.
These 3 new conditions showed similar results to the first presented differentiation and
no specific trend, rendering our first protocol adequate for further attempts at
differentiations.
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Treatment with rhGALNS
The next step taken was to see if these results would be altered upon treatment
with rhGALNS, especially for the expression of genes characteristic of chondrocyte
differentiations. Harvests and subsequent follow-up experiments were done separately
for each clone to avoid confusion. Cells were treated or not with rhGALNS as in the
preceding experiments. The unaffected clone behaved well through differentiation, but
the cell pellets did decrease in size and there was some slight dissociation observed. As
shown in figure 19A, these pellets had an overall positive expression of Col2, which was
slightly lower in treated group. Col2 levels maintained a bell-shaped curve in the nontreated group whereas the treated group had variable Col2 expression (Figure 19B).
There appeared to be a correlation in expression of Col2 and aggrecan as they increase
on the same days as noticed already with the other two clones. Furthermore, aggrecan
levels steadily increased, and no major difference is obvious between the two treatment
groups (Figure 19C). Expression of Sox9 and Col10 was very low in both groups. In
comparison with the preceding experience whereas COL10 was giving the highest
signal.

	
  

53	
  

	
  

	
  
	
  

54	
  

	
   	
  

	
  
The moderate clone pellets saw a challenging differentiation period in which

dissociation occurred often and pellets greatly decreased in size. Harvests had to be
done carefully and RNA extraction was not that difficult since remaining pellet pieces
were not very firm. The qRT-PCR results were especially interesting for this clone. As
can be seen in figure 20A, Col10 expression was relatively high in both groups
compared to the other markers, but the levels of Col10 were markedly reduced upon
treatment with rhGALNS. Also, Sox9 expression was low in both groups. Interestingly,
Col2 and Aggrecan saw a dramatic increase in expression upon treatment at day 30
(Figures 20B, C). This was especially the case for Col2, which saw a 14-fold increase
upon treatment. Aggrecan saw a 8-fold increase in expression as well. These
observations were not apparent before day 30.
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Lastly, the severe clone saw an uneventful differentiation period in which pellets
remained relatively big and only a slight dissociation was observed. Once again, Col10
expression was relatively high with a decrease upon treatment, a similar observation was
made with the moderate clone (Figure 21A). Sox9 expression was higher in this clone,
closely matching the pattern of Col10 expression. Interestingly, there was also a slight
reduction in Sox9 expression with treatment of rhGALNS as well. In comparison,
aggrecan and Col2 expression was very low. As shown in Figure 21B, Col2 expression
has no specific pattern but still quite similar to aggrecan. What is different with this
marker is that there is slight expression even at day 0, and expression level is decreased
at day 25 upon treatment. Aggrecan is also very low, though it increases a bit as
experiment progresses (Figure 21C). However, the levels are not significant and there is
no difference between treatment groups.
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An additional five pellets were cultured for the duration of the differentiation with
the addition of aggrecan, to see if cells could accumulate aggrecan since we have not
been able to see a steady expression of it. These five pellets were prepared for capillary
electrophoresis analysis, a technique used to analyze GAGs, for keratan sulfate and
chondroitin sulfate. As shown in figure 22, there is no detectable KS in any sample.
However, there are detectable peaks with the Chondroitinase digestion, especially in the
severe clone. In the severe clone, it appears that the peaks are reduced upon treatment
with GALNS. Furthermore, calculations of peaks show there is a 20% reduction for the
moderate clone and a 60% reduction of the severe clone upon treatment. These results
are promising but may be due to treatment with Aggrecan. This experiment was not
possible for non-aggrecan-treated pellets since there were no remaining pellets after
harvests.
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IV. Discussion & Conclusion
With the derived iPSCs, an in-depth study of the pathogenesis of MPS IVA is
possible. The reprogramming of patient-specific fibroblasts was successful and shows
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positive expression of pluripotent markers. Thus these iPSCs were used for the further
differentiation of specific cell types, such as chondrocytes, which are extremely important
for studies on Morquio syndrome and which we attempt to differentiate in this study. The
iPSC lines displayed observed differences between them, such as slower growth and
bigger cell size for the clone representing the severe phenotype. However, maintenance
of iPSCs is difficult and requires extensive time commitment.
The direct chondrocytic differentiation of iPSCs was not successful as attested by
the absence of significative chondrogenic marker expression. The cell pellets obtained
using the micromass or pellet techniques dissociated or flattened out during culture, an
issue likely due to iPSC properties or culture conditions. Gene expression analysis
showed that Sox9, the main transcription factor regulating chondrogenesis, and Col2, a
gene characteristic of chondrogenic differentiation as the basis for articular cartilage,
were poorly expressed, suggesting failure to initiate the correct conditions for
chondrogenesis. Furthermore, aggrecan, an important proteoglycan of the chondrocyte
extracellular matrix, was not detected. Aggrecan contains many KS chains, rendering it
as a main source of KS accumulation in MPSIVA. It was apparent through the various
attempts of differentiation, however, that chondrogenic induction in improved upon
supplementation of TGFβ3 instead of TGFβ1. This information was critical for
chondregenic differentiations using MSCs.
As a second option for deriving chondrocytes, we used an indirect approach
requiring the establishment of a mesenchymal stem cell line first. Various protocols were
used, the 1) EB-outgrowth, 2) Low density, and 3) Oldershaw that resulted in different
outcomes. The selected iPSC-derived MSC clones express MSC-specific markers as
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seen through flow cytometric analysis, gene expression analysis, and immunostaining,
confirming its lineage and ability of further differentiation. The culture maintenance of
MSC’s also showed some differences amongst clones, primarily in the growth rate and in
the cell size. These observations lead to a phenotypic investigation of the three clones
with live cell assays and high content screening. It was confirmed that the severe clone
does grow the slowest, which could be a phenotype directly related to disease. Other
experiments showed the severe clone has bigger cell size and increased lysosomal
content or size as well. These results are promising as they show possible phenotypic
differences of the MPSIVA clones. Cells were also subjected to experiments testing the
therapeutic efficiency of rhGALNS to see if the treatment could restore levels to the
unaffected phenotype. Furthermore, it was suggested that the growth rate could be
rescued upon treatment with rhGALNS, but additional experiments would be necessary
to confirm. Immunostaining of treated cells showed colocalization of rhGALNS to the
lysosomes, and levels were decreased to that of the unaffected clone upon treatment.
This suggests a functional in vitro bioassay that can be used for rhGALNS with the
MSCs.
Once the mesenchymal lineage of each clone was confirmed, they were
expanded and banked. Several protocols for chondrocyte differentiations were tried.
Initial differentiations done using the pellet technique with the normal clone showed a
significant and similar expression pattern of Col2 and aggrecan, suggesting
chondrogenesis was reached. The same experiment with the two disease clones,
however, showed opposite results. Expression of Col10 was the highest in this case,
suggesting hypertrophic chondrocytes that may be leaning towards endochondral

	
  

62	
  

ossification. Upon treatment with rhGALNS, expression of aggrecan and Col2 was
greatly recovered in the moderate clone only. Furthermore, expression of Col10 was
reduced upon treatment. These results indicate possible therapeutic benefits to the
directed differentiation of chondrocytes. It can be hypothesized that perhaps the severe
clone would need a long-term treatment with rhGALNS to see similar results observed of
the moderate clone. Capillary electrophoresis analysis for KS and CS shows only an
accumulation of CS, which appears to be reduced with rhGALNS, especially in the
severe clone. This experiment should be repeated for confirmation of these interesting
results.
Further work includes follow-up, in-depth experiments to detect phenotypic
differences amongst clones, with focus on filamentous composition and lysosomal
accumulation. Such experiments should also be attempted upon treatment with
rhGALNS. Also, cell-based assays can be developed with the MSCs, such as the effects
of KS accumulation in lysosomes, gene expression, and therapeutic efficiency. Because
the chondrogenic markers were not expressed equally in each round of differentiation,
this protocol needs to be further optimized or other techniques should be investigated.
Lastly, the established MPSIVA iPSCs can be used to differentiate other relevant cell
types to continue research. With acquired or established cell types, identification and
exploration of cellular pathways involved in MPSIVA is possible.
Our results indicate that MPSIVA cell models by using iPSCs and MSCs are
attainable and could help us expand our knowledge of this disease. This study has
opened a plethora of possibilities and also a lot of questions. A disease model was
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established and a bioassay for rhGALNS using these cells introduced. Using the iPSC
and MSC lines, a promising tool for in vitro studies of MPSIVA is available.
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